Norberg A, Norberg B, Parkhede U, Gippert H, Ekman R
Ups J Med Sci. 1979;84(1):75-82. doi: 10.3109/03009737909179142.
The urine sediment of 12 geriatric patients with indwelling catheters was quantified by the glutaraldehyde-cytocentrifuge method prior to, during and after a clinical trial of methenamine hippurate (MH), 2 g x 3 daily given for 34 days as the sole therapeutic agent for the urinary tract infection. The median leukocyte concentration in the urine of these patients was 100 cells/microliter (Q1 - Q3 50-350), i.e. tenfold higher than the upper normal limits reported in healthy probands. The median bacteriuria in the control period was 12 x 10(5) bacteria/ml urine, interquartile range 10-60 x 10(5) bacteria/ml and extreme individual values 300-500 x 10(5) bacteria/ml. Hematuria, defined as greater than or equal to 24 erythrocytes/microliter urine, was not prominent and could not be correlated with MH treatment, nor with catheter changes. The reported observations suggest that short-term high-dose treatment with MH as sole therapeutic agent reduced pyruria and bacteriuria in the group of patients studied.
在一项关于马尿酸乌洛托品(MH)的临床试验之前、期间和之后,采用戊二醛细胞离心法对12例留置导尿管的老年患者的尿沉渣进行了定量分析。该试验中,将MH作为尿路感染的唯一治疗药物,每日3次,每次2 g,持续给药34天。这些患者尿液中的白细胞浓度中位数为100个/微升(四分位间距为50 - 350),即比健康受试者报告的正常上限高10倍。对照期的菌尿中位数为12×10⁵细菌/毫升尿液,四分位间距为10 - 60×10⁵细菌/毫升,个别极端值为300 - 500×10⁵细菌/毫升。血尿定义为尿液中红细胞≥24个/微升,并不显著,且与MH治疗及更换导尿管均无关联。所报告的观察结果表明,在研究的患者组中,以MH作为唯一治疗药物进行短期高剂量治疗可减少脓尿和菌尿。